Early palliative care reduces hospital readmissions by 23% for patients with cancer
the ONA take:
According to a new study presented at the American Society of Clinical Oncology (ASCO) Palliative Care in Oncology Symposium in Boston, Massachusetts, researchers at Duke University Hospital in Durham, North Carolina, have designed a collaborative approach in cancer care that decreased the number of patients readmitted to the hospital or sent to intensive care.
Their new treatment model consists of medical oncologists and physicians specializing in palliative care rounding together to care for patients with solid tumors. The two types of physicians met multiple times a day to review their patients' care.
Then, the researchers reviewed the 2,353 inpatient encounters that the cooperative team rounded on since 2011. Their analysis showed that there was a 23% reduction in the number of patients readmitted within 1 week of discharge. They also found a 15% reduction in the number of patients transferred to intensive care. The collaborative team model also allowed patients to be discharged approximately 8 hours sooner and hospice referrals rose 17%.
The findings suggest that implementing palliative care sooner in patient care, rather than prolonging palliative care until disease progression, will allow patients to talk about their desired quality of life earlier. The researchers hope to also conduct cost-benefit analyses.
Researchers designed a collaborative approach that decreased the number of patients readmitted.
Doctors at Duke University Hospital have developed a new collaborative model in cancer care that reduced the rates at which patients were sent to intensive care or readmitted to the hospital after discharge. The Duke researchers shared their findings today at the Palliative Care in Oncology Symposium sponsored by the American Society of Clinical Oncology.
In the new treatment model, medical oncologists and palliative care physicians partnered in a "co-rounding" format to deliver cancer care for patients admitted to Duke University Hospital's solid tumor unit. The Duke model fostered collaboration and communication between the specialists, who met several times a day to discuss patient care.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
- Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|